SCHEMBL23382834

SCHEMBL23382834

CCC(C)(C)Oc1ccc(C(=O)OC2(C(F)(F)C(=O)O)CCCCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.48
▸ SLC6A9 P48067 1/20 0.36
▸ TP53 P04637 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ PPARA Q07869 4/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ CTSL P07711 3/20 0.33
▸ CTSB P07858 3/20 0.33
▸ CTSS P25774 3/20 0.33
▸ CTSK P43235 3/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ KDM2B Q8NHM5 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ EPHX2 P34913 1/20 0.33
▸ NR1H4 Q96RI1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23382835 0.88 ADORA3 (0.43) ADORA3SLC6A9TP53HPGDSMN1; SMN2
SCHEMBL23383174 0.87 ADORA3 (0.40) ADORA3SLC6A9SLC6A2SLC6A4SLC6A3
SCHEMBL23382833 0.82 ADORA3 (0.38) ADORA3SLC6A9SMN1; SMN2PPARACTSK
SCHEMBL23383170 0.81 CA12 (0.38) ADORA3
SCHEMBL23383171 0.81 KDM4E (0.37) ADORA3SMN1; SMN2CYP3A4
SCHEMBL23382836 0.80 ADORA3 (0.35) ADORA3SMN1; SMN2PPARACTSKCYP3A4
SCHEMBL23382837 0.80 ADORA3 (0.35) ADORA3SMN1; SMN2PPARACTSKCYP3A4
SCHEMBL23382838 0.80 ELANE (0.49) ADORA3SLC6A2SLC6A4SLC6A3
SCHEMBL23383172 0.79 CYP19A1 (0.37) ADORA3SMN1; SMN2CYP3A4CYP2C9CYP2C19
SCHEMBL23383169 0.78 SMN1; SMN2 (0.34) ADORA3SMN1; SMN2CYP3A4CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process IDUA, SLC6A5, SLC6A9 ADORA3 2841/4885SLC6A9 3/4885TP53 4838/4885
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS IDUA, SLC6A5, SLC6A9 ADORA3 2841/4885SLC6A9 3/4885TP53 4838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback